Heart Failure and Kidney Disease in Type 2 Diabetes: 2 Sides of the Same Coin
- PMID: 36302585
- DOI: 10.1016/j.jacc.2022.08.773
Heart Failure and Kidney Disease in Type 2 Diabetes: 2 Sides of the Same Coin
Keywords: SGLT2 inhibitors; cardiorenal; diabetes type 2; heart failure; kidney disease.
Conflict of interest statement
Funding Support and Author Disclosures Dr Zannad has served on the advisory board, steering committee, or executive committee for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardior, Cereno Scientific, Cellprothera, CEVA, CVRx, KBP Biosciences, Novartis, Novo Nordisk, Merck, Roche, and Vifor Fresenius; and is cofounder of CardioRenal, CVCT, and Eshmoun.
Comment on
-
Cardiovascular Effects of Canagliflozin in Relation to Renal Function and Albuminuria.J Am Coll Cardiol. 2022 Nov 1;80(18):1721-1731. doi: 10.1016/j.jacc.2022.08.772. J Am Coll Cardiol. 2022. PMID: 36302584 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
